Provided by Tiger Trade Technology Pte. Ltd.

Dyne Therapeutics, Inc.

17.14
-1.4100-7.60%
Post-market: 17.140.00000.00%16:34 EDT
Volume:1.77M
Turnover:31.10M
Market Cap:2.83B
PE:-4.93
High:18.92
Open:18.43
Low:17.07
Close:18.55
52wk High:25.00
52wk Low:6.36
Shares:165.03M
Float Shares:152.00M
Volume Ratio:0.64
T/O Rate:1.17%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4740
EPS(LYR):-3.4740
ROE:-55.71%
ROA:-31.16%
PB:2.91
PE(LYR):-4.93

Loading ...

Dyne Therapeutics price target lowered to $50 from $60 at H.C. Wainwright

TIPRANKS
·
Mar 03

U.S. RESEARCH ROUNDUP-Block, Sherwin-Williams, Union Pacific

Reuters
·
Mar 03

Analysts Offer Insights on Healthcare Companies: American Well (AMWL) and Dyne Therapeutics (DYN)

TIPRANKS
·
Mar 03

Dyne’s Larger 2025 Loss And New Shelf Registration Might Change The Case For Investing In Dyne Therapeutics (DYN)

Simply Wall St.
·
Mar 03

Dyne Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 02

Earnings Flash (DYN) Dyne Therapeutics Posts Q4 Net Loss $0.76 a Share, vs. FactSet Est of $0.76 Loss

MT Newswires Live
·
Mar 02

Dyne Therapeutics Q4 net loss narrows, beats analyst expectations

Reuters
·
Mar 02

Dyne Therapeutics Q4 EPS $(0.76) Beats $(0.79) Estimate

Benzinga
·
Mar 02

Dyne Q4 net loss USD 112.0 million on R&D expenses USD 95.4 million for FY 2025 R&D expenses USD 398.3 million

Reuters
·
Mar 02

Dyne Therapeutics Inc: Reaffirming Expected Cash Runway Into Q1 2028

THOMSON REUTERS
·
Mar 02

Corrected-Dyne Therapeutics Q4 EPS USD -0.76 VS. Ibes Estimate USD -0.77 (Corrects Amount)

THOMSON REUTERS
·
Mar 02

Dyne Therapeutics Q4 Basic EPS USD -0.76

THOMSON REUTERS
·
Mar 02

Dyne Therapeutics Q4 EPS USD -0.88 VS. Ibes Estimate USD -0.77

THOMSON REUTERS
·
Mar 02

Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

GlobeNewswire
·
Mar 02

Dyne Therapeutics Inc expected to post a loss of 77 cents a share - Earnings Preview

Reuters
·
Feb 27

Sarepta CEO To Jump Ship After 'Tumultuous' Year

Benzinga
·
Feb 26

Dyne Therapeutics to Participate in Upcoming Investor Conferences

Reuters
·
Feb 25

A Look At Dyne Therapeutics (DYN) Valuation After Orphan Drug Win And Upcoming Neuromuscular Data

Simply Wall St.
·
Feb 23

Dyne Therapeutics announces upcoming presentations at MDA Conference

TIPRANKS
·
Feb 23

Dyne Therapeutics to Present Five Neuromuscular Pipeline Updates at 2026 MDA Clinical & Scientific Conference, No Change to Previously Issued Information

Reuters
·
Feb 23